CANADA IS THE FIRST INDUSTRIALIZED NATION IN THE WORLD TO LEGALIZE CANNABIS
YOU did it! … Thank You!
“First they ignore you, then they laugh at you, then they fight you, then you win.” – Gandhi
“The Power of the People Is Greater Than the People in Power” … Wael Ghonim
BROWSE THE SHOP – T-SHIRTS FOR SALE!
To Our Prime Minister Justin Trudeau and the present sitting Canadian Government:
“Now that our Conservative Ontario Premier has ALLOWED Ontario to open ONLY 25 retail cannabis stores in Ontario until April 2019 due to the cannabis shortage, why doesn’t the FEDERAL Government legalize and regulate Dispensaries AND Craft Growers to fill the void?”
Psilocybin Could Be Legal for Therapy by 2021
The psychoactive ingredient in magic mushrooms could soon be legal to use in a clinical setting
By – SHELBY HARTMAN
For the first time in U.S. history, a psychedelic drug is on the fast track to getting approved for treating depression by the federal government. Late last month, Compass Pathways, a U.K.-based company that researches and develops mental health treatments, announced the FDA granted them what’s called a “breakthrough therapy designation” for their trials into psilocybin, the psychoactive ingredient in psychedelic mushrooms.
Researchers who pioneered psychedelic science agree — this is a landmark moment for their field.
“It really does represent a significant development in the whole history of psychedelic research,” says University of California, Los Angeles psychiatry and behavioral sciences professor Charles Grob, who conducted foundational psilocybin trials at UCLA in the mid-2000s.
To Grob and others, the FDA’s recognition of psilocybin isn’t just about psilocybin; It indicates a larger shift in how the federal government perceives psychedelic drugs. Researchers only began receiving approval to investigate psychedelics in the 90s, after they were banned from science for decades due to their association with Woodstock-era iconoclasts.
In August 2017, the FDA gave its first indication that times were changing when it granted MDMA — often confused with ecstasy — a breakthrough therapy designation for post-traumatic stress disorder. Researchers now see both the success of MDMA and psilocybin as a sign that “the psychedelic renaissance,” the resurgence of psychedelic drug research, is finally helping psychedelic medicine receive the recognition it deserves.
Rick Doblin, founder of the Multidisciplinary Association of Psychedelic Studies (MAPS) and a psychedelic research pioneer, predicts that MDMA and psilocybin could now both be legal by 2021. They wouldn’t be legalized for prescription, but, rather, legalized to be administered by therapists who have been trained in what’s called “psychedelic-assisted psychotherapy.” In the case of psilocybin, a therapist or therapy team meets with the patient prior to their trip to psychologically prepare them; monitors them throughout their trip (typically eight hours or so); and then helps them process their experience afterwards.
If Compass is successful, psilocybin will be approved by the FDA for patients with treatment-resistant depression, or patients who have not responded to traditional anti-depressants. Part of the reason Compass received a breakthrough therapy designation is because there’s a dire need for novel depression treatments in the U.S.
Psilocybin has already proven effective as a mental health treatment in cancer patients suffering from end-of-life distress. Johns Hopkins University, New York University, and UCLA have all conducted trials which have consistently found that a significant number of patients saw their depression and anxiety decrease, if not fully go away, while ranking their trips among the most meaningful experiences of their lives, alongside events like the birth of a first child.
The data from these trials, among others, was used by Compass to receive FDA approval. Researchers are careful to point out, however, that these trials, conducted in cancer patients with end-of-life distress, have limited application for treatment-resistant depression among the general population. There’s only been one promising trial, conducted at the Imperial College London in 2015, looking specifically at treatment-resistant depression — but that only looked at 12 people.
Compass is determined to change that — quickly — and they’re already having unprecedented success in the psychedelic field. They aim to enroll 216 participants in their next round of trials. They have research sites in the United Kingdom and the Netherlands, with the intention of getting psilocybin approved for prescription in Europe, too. Notably, they’re also backed by billionaires including Peter Thiel and ex-hedge fund manager Michael Novogratz, an indication to some researchers in the field that psychedelics have gone mainstream.
There’s only one other organization in the U.S. that’s close to developing a classic psychedelic — MDMA is not considered one of them — into a treatment: a research nonprofit called the Usona Institute. They, too, have received FDA approval for their psilocybin trials in the hopes of getting psilocybin approved for anyone with depression, not just those who are treatment-resistant. Doblin says Compass getting breakthrough therapy designation status should help Usona, or anyone else who wants, get it too.
There’s consensus among the psychedelic community that Compass’ success with the FDA will make it easier for everyone else in the field to get approved for research. If Compass continues to succeed and gets psilocybin approved for depression, Doblin predicts it will be eligible for “off label” prescription, in which doctors will be able to prescribe it for any condition they see fit. That means all the psilocybin research conducted for academic purposes could be used to prescribe psilocybin for conditions like addiction to cigarettes or alcohol.
For the last decade or so, psychedelic pioneers have trodden lightly, concerned that at any moment they might once again lose the freedom to conduct their life’s work. But now, it appears they’ve come too far to go back — and the federal government is finally recognizing it, too.
Canada’s chronic shortage of legal cannabis expected to drag out for years
“WHAT ELSE DID WE EXPECT!”
One industry insider expects shortage to continue until 2022, as more legal cannabis diverted to edibles
Canada’s persistent shortage of legal cannabis could drag on for years. The impending legalization of edible pot will only divert more product away from empty store shelves across the country. One industry insider said he now expects that shortage to endure until 2022.
“If it was just the current product set, I’d say a year to 18 months,” said Chuck Rifici, CEO of the Toronto-based cannabis company Auxly.
“But because we have edibles and a bunch of new product types coming in October, I think it’ll be the better part of three years before we have true equilibrium and oversupply in the space.”
Licensed producers have been adding capacity in droves. Millions of square feet of new greenhouse space has been built since last summer. But for every new gram produced, new demand is piling up as well.
“The medical cannabis market still grows by about five per cent a month,” said Rifici. “We have about 300,000 Canadians accessing medically, so that’s a drain on the system, as well as international exports that are starting to amplify.”
Edibles industry ramps up
Meanwhile, the edible cannabis side of the industry is only starting to ramp up. The makers ofCorona beer and Kim Crawford wines teamed up with Canopy Growth and expect to roll out cannabis-infused beer and wine. Budweiser partnered with Tilray, and Molson-Coors created their own joint venture with Quebec-based Hexo.
Cannabis-infused food and drink promises to open a whole new segment of the market. A recent report by Deloitte found 49 per cent of probable cannabis users in Canada are willing to try edibles. But that growth comes with a whole new batch of regulations and expectations.
Health Canada will require strict rules around shelf life and refrigeration. There will be specific rules around doses per serving. And that’s where Kevin Letun and Pacific Rim Brands hope to step in. His company has partnered with labs at the University of British Columbia in Kelowna and the British Columbia Institute of Technology to dig into the science behind all that.
“Because this is a brand new consumer product and it’s utilizing a schedule-1 drug that’s been illegal for the last 80 years, consumers are going to want to trust the brand that they’re going to be trying in the future,” said Letun.
Right now, Pacific Rim Brands is working on getting the specific formulations for these products. Once that’s completed, the company expects to start human testing to gather data. Essentially, the company is aiming to have formulations ready and approved this summer.
“Then, our goal is to look to either license these to existing beverage companies, potentially licensed producers or even develop our own brands,” said Letun.
Letun said edibles will prove to be a much larger segment of the industry than the current smokeable pot.
“In the next ten years, you’re going to see the smokeable cannabis (comprising) maybe only 10 to 20 per cent of the market,” he said.
He expects edibles and infused drinks will take off once legalized. And he said that will go well beyond cannabis-infused beer and wine.
“There are so many other applications on the medicinal side too, when it comes to sleep aids or sports recovery when it comes to inflammation, pain, sports recovery.”
Public consultations into the legalization of edible cannabis are open now and are expected to conclude at the end of February. As rules become more clear, the summer will see another surge on demand as companies look to get products ready for a market expected to open up on October 17.
It has only been three months since cannabis was legalized in Canada. There’s something to be said for the fact that the highest profile issue to stem from such an enormous change in drug policy is a lack of supply.
That issue is moving toward resolution, perhaps more slowly than expected.
Hamilton Ontario, Canada to Receive 4 of the 25 Cannabis Stores in the Ontario Cannabis Lottery
Shoppers Drug Mart starts selling medical marijuana online January 8th, 2019!
Doctors could tap ‘shrooms to relieve pain
Cannabis Lottery takes place this Friday – January 11th, 2019
What police are getting wrong about pot-impaired driving
Cannabis stores to be phased in with a lottery for licences, Ford government says
Why are so many countries now saying cannabis is OK?
Shoppers Drug Mart gets medical pot licence from Health Canada
Why three of Canada’s Big Cannabis firms scored low on corporate governance rankings
Canada is still using the military to eradicate illegal weed crops
Politics Briefing: Mexico the next in line to legalize cannabis
Ontario ombudsman gets more than 1,000 complaints about cannabis store
Ontario woman upset after legal cannabis shipment arrived late and mouldy
Russia Leads Anti-Drug Bloc’s Condemnation of Canadian Cannabis Legalization
Canada-wide cannabis shortages could last years, producers warn
How Canada Legalized Weed
It’s one of Justin Trudeau’s few policy wins, but he doesn’t deserve all—or even much—of the credit. SHARE TWEET
#TogetherWeDid ! ! !
Legal Cannabis in Canada October 17th!
Alison’s usual Battle Globally, Medical Cannabis …
Why Is Canada Giving All Its Weed Taxes to Cops?
Legal cannabis is here, it’s time to answer some burning questions – CBC NEWS
Tune in Tuesday for Second Part of this Series –
- WATCH: A special one-hour presentation of The National Conversation will air Tuesday Oct. 16 at 8 p.m. ET on CBC News Network and streamed online
Story in the Globe and Mail by one of Alison’s Lawyers Alan Young …
Legalization is only the start: Canada must do right by its ‘cannabis criminals’
CBC Radio One – Toronto, Oct 13, 2018
Our Good Friend Robert “Rosie” Rowbotham talks about
Legalization In Canada on October 17, 2018
No pain is the biggest gain of all for psilocybin user Alison Myrden
Full Story from Psillow – Go to Alison In The News
A team of Johns Hopkins researchers is calling for magic mushrooms to be made legally available as medicine
First time Ever Globally with a Medical #MagicMushroom Authorization!
The Legalization Issue: From medpot to the next frontier – psychedelics as medicine
Full Story from Now Magazine – Go to Alison In The News
Ontario government to allow pot smoking wherever tobacco smoking allowed
Alison was Speaking at Guelph University on September 25, 2018